CN117769434A - 与C1s结合的抗体和其用途 - Google Patents

与C1s结合的抗体和其用途 Download PDF

Info

Publication number
CN117769434A
CN117769434A CN202280048661.4A CN202280048661A CN117769434A CN 117769434 A CN117769434 A CN 117769434A CN 202280048661 A CN202280048661 A CN 202280048661A CN 117769434 A CN117769434 A CN 117769434A
Authority
CN
China
Prior art keywords
antibody
binding fragment
seq
fragment comprises
antibody binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280048661.4A
Other languages
English (en)
Chinese (zh)
Inventor
瓦赫·贝迪安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diannes Medical Operations Co
Original Assignee
Diannes Medical Operations Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diannes Medical Operations Co filed Critical Diannes Medical Operations Co
Publication of CN117769434A publication Critical patent/CN117769434A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280048661.4A 2021-05-20 2022-05-20 与C1s结合的抗体和其用途 Pending CN117769434A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163201952P 2021-05-20 2021-05-20
US63/201,952 2021-05-20
PCT/US2022/030189 WO2022246154A2 (en) 2021-05-20 2022-05-20 Antibodies that bind to c1s and uses thereof

Publications (1)

Publication Number Publication Date
CN117769434A true CN117769434A (zh) 2024-03-26

Family

ID=84141843

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280048661.4A Pending CN117769434A (zh) 2021-05-20 2022-05-20 与C1s结合的抗体和其用途

Country Status (5)

Country Link
US (2) US12252550B2 (enExample)
EP (1) EP4340879A4 (enExample)
JP (1) JP2024518844A (enExample)
CN (1) CN117769434A (enExample)
WO (1) WO2022246154A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023385709A1 (en) 2022-11-21 2025-06-12 Dianthus Therapeutics Opco, Inc. Antibodies that bind to c1s and uses thereof
JP2026510831A (ja) 2023-03-16 2026-04-10 ジェンザイム・コーポレーション 萎縮型加齢黄斑変性の治療
US20250206814A1 (en) * 2023-12-20 2025-06-26 Dianthus Therapeutics Opco, Inc. Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same
WO2025129535A1 (en) * 2023-12-20 2025-06-26 Dianthus Therapeutics Opco, Inc. Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same
TW202547886A (zh) * 2024-02-02 2025-12-16 美商黛安瑟斯醫療運營公司 用於治療ｃ１ｓ介導的疾病和病症的組成物、劑量和方法
WO2025255340A2 (en) 2024-06-05 2025-12-11 Genzyme Corporation BINDING PROTEINS THAT TARGET aC1s, TfR, OR BOTH, AND COMPOSITIONS THEREOF

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2833917C (en) * 2011-04-28 2020-04-28 The Board Of Trustees Of The Leland Stanford Junior University Identification of polynucleotides associated with a sample.
PL2914291T3 (pl) * 2012-11-02 2022-10-03 Bioverativ Usa Inc. Przeciwciała anty-C1s dopełniacza i ich zastosowania
WO2014186622A2 (en) 2013-05-15 2014-11-20 Annexon, Inc. Methods of treatment for guillain-barre syndrome
EP3055328A1 (en) 2013-10-11 2016-08-17 F. Hoffmann-La Roche AG Nsp4 inhibitors and methods of use
PL3280440T3 (pl) * 2015-04-06 2023-06-19 Bioverativ Usa Inc. Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
EP4652926A3 (en) 2016-10-12 2026-03-18 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
US11359018B2 (en) 2016-11-18 2022-06-14 Symphogen A/S Anti-PD-1 antibodies and compositions
BR112019018950A2 (pt) 2017-03-14 2020-04-22 Bioverativ Usa Inc. métodos para tratamento de doenças e distúrbios mediados por complemento
EP3710589A4 (en) * 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
WO2022046888A1 (en) 2020-08-25 2022-03-03 Target Discovery Merger Sub II, LLC Sars-cov-2 associated antibody compositions and methods of use

Also Published As

Publication number Publication date
JP2024518844A (ja) 2024-05-07
WO2022246154A3 (en) 2023-01-12
WO2022246154A2 (en) 2022-11-24
US12252550B2 (en) 2025-03-18
US20220380483A1 (en) 2022-12-01
US20260022195A1 (en) 2026-01-22
EP4340879A4 (en) 2025-03-26
EP4340879A2 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
EP3668897B1 (en) Binding agents
US12252550B2 (en) Antibodies that bind to C1S and uses thereof
CN114316061B (zh) 针对血浆激肽释放酶和因子xii的双特异性抗体
RU2771384C2 (ru) Фармацевтическая композиция, содержащая антитело к lag-3, и ее применение
CN103154029B (zh) 抗人tweak的抗体及其用途
US12415861B2 (en) Anti C-MET antibodies
WO2015085847A1 (zh) Pd-1抗体、其抗原结合片段及其医药用途
US12110344B2 (en) Antibodies that bind to cis and uses thereof
WO2019170885A1 (en) Pd1 binding agents
JP7675193B2 (ja) 血漿カリクレイン抗体及びその使用
US20230406942A1 (en) Igf1r antibodies
EP4257603A1 (en) Pharmaceutical composition comprising anti-connective tissue growth factor antibody
US20260139047A1 (en) Pharmaceutical composition containing fusion protein
RU2797348C2 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22
HK40128682A (zh) 结合c1s的抗体和其用途
WO2023250415A2 (en) Antibodies against integrin alpha 11 beta 1 and uses thereof
KR20250124805A (ko) Cd24에 대한 항체 및 이의 용도
EA052645B1 (ru) Композиция для лечения и предупреждения covid-19
HK40049308A (en) Anti-lag-3 agonistic antibodies
EA052946B1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22
HK40028664A (en) Binding agents
HK40028664B (en) Binding agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination